Journal
JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE
Volume 27, Issue 3, Pages 411-420Publisher
AMER BOARD FAMILY MEDICINE
DOI: 10.3122/jabfm.2014.03.130224
Keywords
Inflammatory Bowel Diseases; Immunomodulatory Therapy; Biologic Therapy
Categories
Ask authors/readers for more resources
Primary care physicians care for patients with inflammatory bowel disease (IBD) who are receiving advanced therapies that include immunomodulator drugs (eg, azathioprine and methotrexate) and biologic therapy. These agents have significantly improved remission rates and the quality of life for patients suffering from IBD. However, patients taking these drugs need special care and counseling with regard to adverse effects, infection risk, cancer risk, and pregnancy. Newer treatment paradigms incorporate earlier use of biologic therapy, often in combination with immunomodulator drugs, to alter the natural course of the disease. Comprehensive care for these patients, including health maintenance, requires collaboration between primary care physicians and gastroenterologists. Despite their high cost, advanced therapies are likely to be cost-effective. This article discusses general concepts about azathioprine, 6-mercaptopurine, methotrexate, and common biologic drugs used in IBD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available